This study aims to assess the safety and clinical accuracy of the SIRA-1000, SIRA® RFA Electrosurgical Device in ablating margins post-lumpectomy in patients undergoing breast conserving surgery for breast cancer. Radiofrequency ablation, or RFA, uses radio waves to create heat, that in turn, causes deliberate controlled damage to the tissue surrounding where the tumor was located. You may hear your doctor refer to this as the 'margins'. Your doctor is using this treatment to help destroy remaining cancer cells in the margins around the site of the lump.
Biologic female
50 years of age and older
Infiltrating ductal carcinoma
ER/PR+Her2neu-
Pregnant or breastfeeding
Neoadjuvant chemotherapy
Cardiac arrhythmia
Patients with active implantable medical devices, such as implanted cardiac pacemakers or defibrillators, or any other electronic device
Single group
Radiofrequency ablation alone
DeviceDemonstrate the accuracy of the device to produce approximately 1 cm depth of ablation around the tumor bed, as evaluated by post-ablation tissue samples at least 1cm deep.
Radiofrequency ablation Electrosurgical Device
DeviceSIRA-1000 an radiofrequency ablation device, is designed to fit the post-lumpectomy cavity to provide uniform ablation.
To assess the safety of SIRA-1000 by summarizing the occurrence of Adverse Events.
Assess the occurrence adverse events and to evaluate the impact of RFA on healing process.
Healing Process assessed by BREAST-Q Questionnaire
Assess healing process using cosmesis and quality of life patient reported outcomes.
Click on the lead sponsor to view all of their trials.
